Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Starbucks

Lowe's

The Fed's inflation-fighting war path is painful but necessary to avoid a far worse fate, a potentially decade-long stagflation hell. When the 2023 recession is over, stocks are likely to soar and make all this short-term pain worth it - potentially with 3X historical returns over 10 years after a 25% bear market.

Starbucks Is A Bargain, And So Are These 2 Faster-Growing Dividend Aristocrats

EXTON, Pa. , Oct. 13, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter 2022 financial results before the market opens on Thursday, October 27, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host Third-Quarter 2022 Conference Call

EXTON, Pa. , Oct. 6, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it has been shortlisted for Company of the Year for 2022 Global Generics and Biosimilar Awards, which will be announced during CPhI Worldwide in Frankfurt, Germany on November 2, 2022. "West is honored to be shortlisted for the Global Generics and Biosimilar 2022 Company of the Year Award," said David Maier, Vice President & General Manager at West Pharmaceutical Services.

West Announced as Company of the Year Finalist for Global Generics and Biosimilar Awards 2022

Albemarle

Cincinnati Financial

Ecolab

W.W. Grainger

Medtronic

Nucor

Realty Income Corp

Sherwin-Williams

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

Walgreens

NOBL fell 2.78% in August which brings the Funds return for the year to a loss of 9.16%. Thus far, through September 23rd, the dividend aristocrat ETF is down 6.71%, bringing its year-to-date return to -15.25%.

My Best Dividend Aristocrats For October 2022

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Here's Why You Should Retain West Pharmaceutical (WST) Now

West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.

West Pharmaceutical's (WST) Latest Investment to Boost Business

EXTON, Pa. , Aug. 11, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery. "West's investment in Latch Medical advances our leadership in innovation through a dedicated focus on the needs of patients," says Robert Segura, Vice President, Corporate Development, West Pharmaceutical Services.

West Makes Minority Investment in Dublin-Based Latch Medical, a Developer of Vaccine and Biologics Delivery Platforms

West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2022 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Quintin Lai – Vice President, Investor Relations Eric Green – Chief Executive Officer Bernard Birkett – Chief Financial Officer Conference Call Participants Derik de Bruin – Bank of America Paul Knight – KeyBanc Larry Solow – CJS Securities Justin Lin – William Blair Jacob Johnson – Stephens Dave Windley – Jefferies Operator Good day, and thank you for standing by. Welcome to the Q2 2022 West Pharmaceutical Services Conference Call.

West Pharmaceutical Services, Inc.'s (WST) CEO Eric Green on Q2 2022 Results - Earnings Call Transcript

West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.

West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut

West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

West Announces Second-Quarter 2022 Results

EXTON, Pa. , July 27, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the Company's Board of Directors has elected Stephen Lockhart, M.D., Ph.D., as its newest member.

West Elects New Director to the Board

EXTON, Pa. , July 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2022 financial results before the market opens on Thursday, July 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host Second-Quarter 2022 Conference Call

EXTON, Pa. , July 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has recently released its 2021 Corporate Responsibility Report, reporting on the Company's environmental, social, and governance (ESG) performance in 2021. This is West's 6th annual CR Report, and highlights ESG successes from over the past year, including progress on environmental sustainability goals, diversity and inclusion, and success around the Company's philanthropic efforts.

West Pharmaceutical Services Releases 2021 Corporate Responsibility Report

West Pharmaceutical Services has performed extraordinarily well in recent years. The future of the enterprise looks bright and the company will likely continue to fare well in the years to come.

West Pharmaceutical Services: A Great Business At A Lofty Price

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

EXTON, Pa. , June 13, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc.  (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will unveil its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention, taking place in San Diego, CA from June 13-16, 2022. Daikyo Crystal Zenith® (CZ®) is a technologically advanced cyclic olefin polymer containment and delivery system that offers an alternative to glass, mitigating the risk of breakage and reducing the chance of particulates, contamination, and extractables.

West Introduces Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention

The DeltaCube™ Modeling Platform is an analytics platform aimed at container closure system (CCS) selection, optimization, and usage EXTON, Pa. , May 24, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it received the Biotech Innovation Award for the DeltaCube™ Modeling Platform at the INTERPHEX 2022 Technical Conference in New York City.

West Receives Exhibitor Award at INTERPHEX 2022 for Proprietary DeltaCube™ Modeling Platform

West to present on industry trends, enabling technologies, packaging components, and innovative DeltaCube™ Modeling Platform EXTON, Pa. , May 23, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at INTERPHEX 2022 to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

West to Attend and Showcase Industry Leadership in Packaging and Containment at INTERPHEX 2022

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why West Pharmaceutical Services (WST) is a Strong Growth Stock

EXTON, Pa. , May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer.

West Announces Executive Leadership Appointments

West Pharmaceutical Services, Inc. (NYSE:WST ) Q1 2022 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Quintin Lai - VP, IR Eric Green - President and CEO Bernard Birkett - CFO Conference Call Participants Larry Solow - CJS Securities Justin Lin - William Blair Paul Knight - KeyBanc Jacob Johnson - Stephens Derik De Bruin - Bank of America Dave Windley - Jefferies Operator Good day and thank you for standing by. Welcome to the Q1 2022 West Pharmaceutical Services Earnings Conference Call.

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q1 2022 Earnings Call Transcript

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

West Pharmaceutical Services Inc (NYSE: WST) reported first-quarter FY22 sales growth of 7.4% year-on-year to $720 million, missing the consensus of $720.92 million. Proprietary products segment revenue grew 10.6% Y/Y to $601.3 million.

News for West Pharmaceutical Services Stock (WST)